498 related articles for article (PubMed ID: 35788937)
1. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer.
Liu C; Liao J; Wu X; Zhao X; Sun S; Wang H; Hu Z; Zhang Y; Yu H; Wang J
Thorac Cancer; 2022 May; 13(10):1463-1470. PubMed ID: 35388976
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of anlotinib in combination with standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A multi-center, prospective study (ACTION-2).
Zhang W; Deng P; Kong T; Zhang B; Qian F; Dong Y; Chen Y; Chen L; Liu D; Zhang Y; Yang H; Han B
Lung Cancer; 2022 Nov; 173():43-48. PubMed ID: 36116169
[TBL] [Abstract][Full Text] [Related]
4. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
[TBL] [Abstract][Full Text] [Related]
5. Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: A single-arm trial.
Deng P; Hu C; Chen C; Cao L; Gu Q; An J; Qin L; Li M; He B; Jiang J; Yang H
Cancer Med; 2022 Oct; 11(19):3563-3571. PubMed ID: 35526266
[TBL] [Abstract][Full Text] [Related]
6. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial.
Wu Y; Zhou X; Zhao W; Wang Q; Han Z; Wang L; Zhou W; Zhou T; Song H; Chen Y; Yang K; Shi L; Pan B; Guo R; Zhou G; Jiang F; Feng J; Shen B
Invest New Drugs; 2023 Dec; 41(6):825-833. PubMed ID: 37837490
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer.
Nogami N; Tokito T; Zenke Y; Satouchi M; Seto T; Saka H; Ohtani J; Han S; Noguchi K; Nishio M
Invest New Drugs; 2024 Feb; 42(1):136-144. PubMed ID: 38300341
[TBL] [Abstract][Full Text] [Related]
9. Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer.
Reck M; Horn L; Novello S; Barlesi F; Albert I; Juhász E; Kowalski D; Robinet G; Cadranel J; Bidoli P; Chung J; Fritsch A; Drews U; Wagner A; Govindan R
J Thorac Oncol; 2019 Apr; 14(4):701-711. PubMed ID: 30677506
[TBL] [Abstract][Full Text] [Related]
10. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
[TBL] [Abstract][Full Text] [Related]
11. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
[TBL] [Abstract][Full Text] [Related]
13. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
Asao T; Watanabe S; Tanaka T; Morita S; Kobayashi K
BMC Cancer; 2022 Nov; 22(1):1135. PubMed ID: 36333680
[TBL] [Abstract][Full Text] [Related]
15. A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.
Glisson B; Besse B; Dols MC; Dubey S; Schupp M; Jain R; Jiang Y; Menon H; Nackaerts K; Orlov S; Paz-Ares L; Ramlau R; Tang R; Zhang Y; Zhu M
Clin Lung Cancer; 2017 Nov; 18(6):615-625.e8. PubMed ID: 28601388
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
Morikawa N; Inoue A; Sugawara S; Maemondo M; Harada T; Harada M; Fujita Y; Katoh T; Yokouchi H; Watanabe H; Usui K; Suzuki T; Sakakibara-Konishi J; Nagai H; Kanbe M; Nukiwa T
Lung Cancer; 2017 Sep; 111():38-42. PubMed ID: 28838395
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans.
Azar I; Yazdanpanah O; Jang H; Austin A; Kim S; Chi J; Alkassis S; Saha BK; Chopra A; Neu K; Mehdi S; Mamdani H
JAMA Netw Open; 2022 Oct; 5(10):e2237699. PubMed ID: 36264573
[TBL] [Abstract][Full Text] [Related]
18. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Wang J; Zhou C; Yao W; Wang Q; Min X; Chen G; Xu X; Li X; Xu F; Fang Y; Yang R; Yu G; Gong Y; Zhao J; Fan Y; Liu Q; Cao L; Yao Y; Liu Y; Li X; Wu J; He Z; Lu K; Jiang L; Hu C; Zhao W; Zhang B; Shi W; Zhang X; Cheng Y;
Lancet Oncol; 2022 Jun; 23(6):739-747. PubMed ID: 35576956
[TBL] [Abstract][Full Text] [Related]
19. Durvalumab: A Review in Extensive-Stage SCLC.
Al-Salama ZT
Target Oncol; 2021 Nov; 16(6):857-864. PubMed ID: 34731446
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
